Zura Bio Limited last reported quarterly results on Oct 27, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): diluted EPS of -$0.20. It usually reports 27–57 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 25, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Feb 26, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 27–57 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 27, 2026
27 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
—
|
-26
-43.2%
|
-0.20
+4.8%
|
|
Aug 11, 2026
42 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
—
|
-26
-64.5%
|
-0.21
-23.5%
|
|
May 7, 2026
37 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
—
|
-24
-38.9%
|
-0.22
-15.8%
|
|
Feb 26, 2026
57 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
—
|
-17
-26.1%
|
-0.48
-385.5%
|
|
Nov 13, 2025
44 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
—
|
-18
+12.9%
|
-0.21
+19.2%
|
|
Aug 14, 2025
45 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
—
|
-16
-54.8%
|
-0.17
+0.0%
|
|
May 8, 2025
38 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
—
|
-17
-125.1%
|
-0.19
-850.0%
|
|
Nov 7, 2024
38 days after quarter end
|
—
ended Sep 30, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ZURA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- La Jolla, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1855644
- Former names
- JATT Acquisition Corp (until Mar 21, 2023)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.